Home / Fact sheets / Population fact sheet

Country fact sheet: France

Population

- Total population: 66 892 205
- Female population: 34 013 206
- Male population: 32 878 999
The World Bank (2016)

Health Expenditure

- Total per capita (US$): 4 026.1
- Out-of-pocket (% of total expenditure on health): 6.8
World Health Organization (2015)

Human Development Index

- HDI: 0.897
- Category: Very high
UNDP Human Development Report (2015)

Geography

Life Expectancy at Birth

- Total population (years): 82.3
- Female population (years): 85.5
- Male population (years): 79.2
The World Bank (2016)

Cancer Burden

- Overall cancer incidence (rate per 100 000 persons per year): 344.1
- Overall cancer mortality (rate per 100 000 persons per year): 109.8
- Most common cancer site by incidence for females (rate per 100 000 persons per year): Breast (99.1)
- Most common cancer site by mortality for females (rate per 100 000 persons per year): Breast (15.4)
- Most common cancer site by incidence for males (rate per 100 000 persons per year): Prostate (99.0)
- Most common cancer site by mortality for males (rate per 100 000 persons per year): Lung (38.9)
- GLOBOCAN 2018 population fact sheet
GLOBOCAN (2018)

Screening programmes

       

BREAST CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2012
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Mammography + CBE/US
(50-74 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy:
Program introduction was preceded by a pilot:
Year program was initiated: 2004
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual and aggregate
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with Population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data:
Annual target for screening coverage:
Invitations to eligible population:
Method of invitation:
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based and non population-based
Current status of implementation (applicable only for population-based programmes):
Cancer screening programme population based for selected populations:

Performance indicators

Target age and regional limitation if applicable: 50-69 years
Invitation coverage (%): 102.7
Examination coverage (%): 52.3
Participation rate (%): 51
Completeness of data related to screening results (%): 99.4
Completeness of data related to further assessment results (%): 94.4
Further assessment rate (%): 9.4
Further assessment participation rate (%): 96.0
Detection rate of CIS and invasive (x 1000): 6.74
Detection rate of invasive cancer (x 1000): 1.02
Positive predictive value of further assessment to detect CIS and invasive (%): 7.5
Proportion of total carcinomas which are CIS (%): 15.1
Benign surgical biopsy rate (x 1000): 1.26
More quantitative data (2012)



CERVICAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2010-2012
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Cytology
(25-64 years / [36 months] )
Triaging test used: None
"screen and treat" included in the protocol:

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy:
Program introduction was preceded by a pilot:
Year program was initiated: 1991
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual and aggregate
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: Population register
Annual target for screening coverage:
Invitations to eligible population: Excluding those covered by opportunistic screening
Screening kit included with the invitation:
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based and non population-based
Current status of implementation: Roll-out on going
Cancer screening programme population based for selected populations/regions:

Performance indicators

Target age and regional limitation if applicable: 30-59 years (13 regions)
Invitation coverage (%): 53.6
Examination coverage (invitation cohort) (%): 11.7
Examination coverage (tests in the index-year) (%): 63.1
Participation rate (%): 21.9
Completeness of data related to screening test results (%):
Completeness of data related to further assessment results (%):
Colposcopy referral rate (%):
Colposcopy participation rate (%):
Detection rate of CIN2+ (x 1000):
Detection rate of CIN3+ (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value of CIN3+ (x 1000):
More quantitative data (13 regions: 2010-2012)



COLORECTAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2012
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2012
Source of data: No source

Screening protocol

Year published/updated:
Screening test used: 2
Target age (min-max) and screening interval [months] for each test: FIT: (50-74 years / [24 months] )
gFOBT: (50-74 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2002
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual and aggregate
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry:

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: List from insurance company
Annual target for screening coverage:
Invitations to eligible population: For the entire target population
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based and non population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations:

Performance indicators

FIT gFOBT sigmoidoscopy Colonoscopy
Target age and regional limitation if applicable: 50-74 (Calvados) 50-74
Invitation coverage (%): 88.2 97.0
Examination coverage (%): 20.1 23.7
Participation rate (%): 22.8 24.4
Completeness of data related to screening results (%): 99.2 97.9
Completeness of data related to information about attendance to colonoscopy assessment (%): 100.1 100.0
Completeness of data related to histology result (%): 99.9 99.0
Screen positivity (indication for follow-up colonoscopy) rate (%) : 3.3 2.2
Follow-up colonoscopy participation rate (%): 87.9 84.0
Completion rate follow-up colonoscopy (%): 93.8 93.8
Detection rate of adenomas (x 1000): 10.7 6.1
Detection rate of advanced adenomas (x 1000): 6.0 3.6
Detection rate of colorectal cancers (x 1000): 1.8 0.6
Positive Predictive Value of further assessment to detect adenomas (%): 37.5 33.6
Positive Predictive Value of further assessment to detect advanced adenomas (%): 21.2 19.8
Positive Predictive Value of further assessment to detect colorectal cancers (%): 6.3 3.5
More quantitative data for gFOBT (Male - 2012)
More quantitative data for gFOBT (Women - 2012)
More quantitative data for FIT (Male - Calvados: 2012)
More quantitative data for FIT (Women - Calvados: 2012)